Neurothera Labs Inc.
NTLX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -38.18% | -38.18% | -22.82% | -9.23% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -38.18% | -38.18% | -22.82% | -9.23% | |
| Cost of Revenue | -28.71% | -28.71% | -84.26% | -23.08% | |
| Gross Profit | -40.83% | -40.83% | 176.64% | -1.78% | |
| SG&A Expenses | 176.04% | 176.04% | 154.75% | -23.08% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 58.73% | 58.73% | 11.76% | -23.08% | |
| Operating Income | -98.40% | -98.40% | -15.08% | 44.38% | |
| Income Before Tax | -94.49% | -94.49% | -17.55% | 44.38% | |
| Income Tax Expenses | -- | -- | 280.00% | -- | |
| Earnings from Continuing Operations | -94.49% | -94.49% | -17.92% | 44.38% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -19.28% | -19.28% | -79.75% | -- | |
| Net Income | -103.55% | -103.55% | -68.44% | 44.38% | |
| EBIT | -98.40% | -98.40% | -15.08% | 44.38% | |
| EBITDA | -108.64% | -108.64% | -17.74% | 40.49% | |
| EPS Basic | -37.47% | -37.47% | -25.58% | -- | |
| Normalized Basic EPS | -41.69% | -41.69% | -1,057.05% | -- | |
| EPS Diluted | -37.47% | -37.47% | -25.58% | -- | |
| Normalized Diluted EPS | -41.69% | -41.69% | -1,057.05% | -- | |
| Average Basic Shares Outstanding | 48.13% | 48.13% | 34.12% | -- | |
| Average Diluted Shares Outstanding | 48.13% | 48.13% | 34.12% | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |